Clinical trials: Crohns Disease
Crohn's Disease
Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients
The objectives of this study were to assess the safety and tolerability of LDP-02 in patients with active Crohn's disease who were not receiving corticosteroids or immunosuppressives, to assess the ability of LDP-02 to reduce…
- Trial name
- NCT00655135
- Testing
- LDP-02
- Volunteers
- 185 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Moderate to Severe Crohn's Disease
NI-0401 in Active Crohn's Disease
The purpose of the study is to assess the safety and tolerability of daily intravenous NI-0401 treatment, compared to matching placebo. And to assess the ability of NI-0401 to modulate the CD3 complex on T-cells.
- Trial name
- NCT00630643
- Testing
- NI-0401 (anti-CD3 mAB)
- Volunteers
- 40 people
- Sponsor
- Light Chain Bioscience - Novimmune SA
Crohn's Disease
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to…
- Trial name
- NCT00338650
- Testing
- adalimumab
- Where
- 97 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Abbott
Crohn's Disease
An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of Inflabloc Cap (Dehydroepiandrosterone [DHEA]) in the treatment of patients with moderately active Crohn's disease.
- Trial name
- NCT00106314
- Testing
- Dehydroepiandrosterone [DHEA]
- Where
- 38 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Inflabloc Pharmaceuticals
Crohn's Disease
Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
- Trial name
- CHARM (NCT00077779)
- Testing
- Adalimumab
- Where
- 43 sites in United States
- Volunteers
- 854 people
- Sponsor
- Abbott
Crohn's Disease
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy.
- Trial name
- NCT00074542
- Testing
- Epanova™ (Omega-3 Free Fatty Acids)
- Where
- 31 sites in United States, Canada
- Volunteers
- 364 people
- Sponsor
- Tillotts Pharma AG
Crohn's Disease
Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease
The purpose of this study is to determine whether C326, a new inhibitor of IL-6, is safe in patients with Crohn's disease.
- Trial name
- NCT00353756
- Testing
- C326, IL-6 Inhibitory Avimer protein
- Where
- 2 sites in Australia
- Volunteers
- 52 people
- Sponsor
- Avidia
Crohn's Disease
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance)
- Trial name
- NCT00055523
- Testing
- Adalimumab (D2E7)
- Where
- 43 sites in United States
- Volunteers
- 300 people
- Sponsor
- Abbott
Crohn's Disease
Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
The goal of this study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease who have been initially treated with infliximab and either lost response or discontinued its use as a…
- Trial name
- NCT00105300
- Testing
- Adalimumab
- Where
- 56 sites in United States, Belgium and 2 more
- Volunteers
- 300 people
- Sponsor
- Abbott
Crohn's Disease
STA-5326 in Crohn's Disease Patients
The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.
- Trial name
- NCT00088062
- Testing
- STA-5326
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- Synta Pharmaceuticals Corp.